Momenta Pharmaceuticals Inc. (MNTA)
Symbol Info
Listed Symbol MNTA
Name Momenta Pharmaceuticals Inc.
Share Info
Annual Info
Latest Fiscal Dividend Per Share $-
Latest Fiscal Date 2018-12-31
Latest Fiscal Revenue $75,589,000
Latest Fiscal EPS $-2.25
Price Info
21 Day Moving Average $12.7181
21 Day EMA $12.814500
50 Day Moving Average $11.7410
50 Day EMA $12.323270
200 Day EMA $13.503210
200 Day Moving Average 12.535650
52 Week High $29.30
52 Week Low $9.51
52 Week Change $-49.504600
Alpha 0.000841
Beta 2.0330
Standard Deviation 0.156430
R2 0.200761
Periods 60
Share Information
10 Day Average Volume 486,632
20 Day Average Volume 455,517
30 Day Average Volume 527,403
50 Day Average Volume 523,078
Outstanding Shares 98,707,302
Float Shares 94,500,475
Percent Float 95.74%
Short Interest -
Short Percent Float -
Short Interest Ratio -
Short Date
Holders
Institutions 347
Institute Holdings Date 2019-08-31
Institute Bought Previous 3 Months 3,355,305
Institute Holdings Percent -
Institute Sold Previous 3 Months 7,265,484
Insider Holdings Date 2019-08-31
Insider Bought Previous 3 Months 23
Insider Holdings Percent 4.30%
Insider Sold Previous 3 Months -
Insiders Shares Owned 4,206,827
Price Change
7 Day Price Change $0.9700003
7 Day Percent Change 7.58%
21 Day Price Change $1.7399998
21 Day Percent Change 14.48%
30 Day Price Change $1.8900003
30 Day Percent Change 15.92%
Month To Date Price Change $1.1300
Month To Date Percent 8.95%
90 Day Price Change $1.620000
90 Day Percent Change 13.34%
Quarter To Date $1.310000
Quarter To Date Percent 10.52%
180 Day Price Change $-0.429999
180 Day Percent Change -3.03%
200 Day Price Change $-0.73
200 Day Percent Change -5.04%
Year To Date $2.720000
Year To Date Percent 24.64%
Profile
Description Momenta is a biotechnology company focused on the characterization and development of innovative drugs in autoimmune diseases. Its legacy business includes complex generic versions of MS drug Copaxone and anticoagulant Lovenox, and it receives royalties for these products through a partnership with Novartis. While biosimilar versions of Humira and Eylea are in the pipeline, Momenta terminated future development in generics/biosimilars in 2018. Several innovative drugs, including M281, M254, and M230, are in development to treat rare autoimmune diseases.
Details
Issue Type CS
Market Cap $1,358,212,476
Sec Type EQS
Auditor Ernst & Young LLP
Total Shares Outstanding 98,707,302
CEO Craig A. Wheeler
Employees 131
Last Audit UE
Classification
CIK 0001235010
Industry Drug Manufacturers
Sector Healthcare
NAICS Biological Product (except Diagnostic) Manufacturing(325414)
Info
Address 301 Binney Street
Cambridge, MA 2142
Website http://www.momentapharma.com
Facisimile +1 617 621-0431
Telephone +1 617 491-9700
Email IR@momentapharma.com
Key Ratios
Profitability
EBIT Margin -310.8
EBITDA Margin -284.8
Pre-Tax Profit Margin -119.4
Profit Margin Cont -
Gross Margin -78.4
Profit Margin TOT -
Income Statements
Revenue $67,001,000
Revenue Per Share $0.6788
Revenue 3 Years $-9.21
Revenue 5 Years $9.74
Valuation Measures
PE Ratio -
Enterprise Value $1,188,101,278
Price To Sales 20.271526
Price To Free Cash -7
PE High Last 5 Years -
Price To Book 4.4
Price To Cash Flow 23.5
PE Low Last 5 Years -
Price To Tangible Book 4.4
Financial Strength
Total Debt To Equity 0.3
Int Coverage -
Current Ratio 7.6
Leverage Ratio 1.3
Quick Ratio 6.6
Long Term Debt To Capital 0.20
Assets
Receivables Turnover 2.6
Invoice Turnover -
Assets Turnover 0.10
Management Effectiveness
Return Assets -49.67
Return On Equity -73.13
Return On Capital -56.22
Dividends
Dividend 3 Years $-
Dividend 5 Years $-
Ex Dividend Date
Dividend Rate $-
Dividend Yield -
Payment Type


Your Recent History
NASDAQ
MNTA
Momenta Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.


NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.